menu

Fatty Liver or NASH: The Future of Noninvasive Diagnosis and Assessment

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Fatty Liver or NASH: The Future of Noninvasive Diagnosis and Assessment

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • In Collaboration with

  • Overview

    The use of noninvasive tools in NAFLD/NASH has become more prevalent over the last several years, with increased availability of imaging and serum-based tools. A forum of experts convened to discuss optimal use of these tools in NAFLD/NASH using a series of clinical assertion statements. These statements covered screening patients with diabetes, applicability of liver enzymes in determining fibrosis stage, use of transient elastography and blood-based tools, such as the Enhanced Liver Fibrosis test, and potential genetic testing. Here, Drs Jacobson and Younossi summarize the research and discussion points from the forum.

  • Disclosure of Conflicts of Interest

    The “Policy on Identification, Mitigation and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that all individuals in control of educational content of a CME/CE activity disclose all financial relationships with ineligible companies* within the previous 24-month period. Any individual whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present. All relevant financial relationships and potential conflicts of interest are mitigated prior to the activity.

    *The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

    Ira M. Jacobson, MD
    Disclosures: Grant/Research Support: Assembly Biosciences, Bristol Myers Squibb, Durect, Eli Lilly, Enanta, Genfit, Gilead, Janssen and Myr; Honorarium: AbbVie, Aligos, Arbutus, Arrowhead, Assembly Biosciences, Bristol Myers Squibb, Galmed, Gilead, Glaxo, Intercept, Janssen, Poptest and Redhill

    Zobair M. Younossi MD, MPH, FACP, FACG, AGAF, FAASLD
    Disclosures: Consultant: Abbvie, Bristol-Myers Squibb, Genfit, Gilead Sciences, Intercept, Madrigal, Merck, NovoNordisk, Siemens, Terns Pharmaceuticals, Inc., Viking Therapeutics

    Aaron Z. Tokayer, MD
    No financial relationships with an ACCME-defined ineligible company in the last 24 months

    Planning Committee Members
    Quentin M. Anstee, PhD, FRCP
    Disclosures:
    Research Grant Funding: Abbvie, Allergan/Tobira, AstraZeneca, GlaxoSmithKline, Glympse Bio, Novartis Pharma AG, Pfizer Ltd., Vertex. Active Research Collaborations (including research collaborations supported through the EU IMI2 LITMUS Consortium*): Abbvie, Antaros Medical*, Allergan/Tobira*, AstraZeneca*, BMS*, Boehringer Ingelheim International GMBH*, Echosens*, Ellegaard Gottingen Minipigs AS*, Eli Lilly & Company Ltd.*, Exalenz Bioscience Ltd.*, Genfit SA*, Glympse Bio, GlaxoSmithKline, HistoIndex*, Intercept Pharma Europe Ltd.*, iXscient Ltd.*, Nordic Bioscience*, Novartis Pharma AG*, Novo Nordisk A/S*, One Way Liver Genomics SL*, Perspectum Diagnostics*, Pfizer Ltd.*, Resoundant*, Sanofi-Aventis Deutschland GMBH*, SomaLogic Inc.*, Takeda Pharmaceuticals International SA*; Consultancy: 89Bio, Abbott Laboratories, Acuitas Medical, Allergan/Tobira, Altimmune, AstraZeneca, Axcella, Blade, BMS, BNN Cardio, Celgene, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company Ltd., Galmed, Genentech, Genfit SA, Gilead, Grunthal, HistoIndex, Indalo, Imperial Innovations, Intercept Pharma Europe Ltd., Inventiva, IQVIA, Janssen, Madrigal, MedImmune, Metacrine, NewGene, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S, PathAI, Pfizer Ltd., Poxel, ProSciento, Raptor Pharma, Servier, Terns, Viking Therapeutics; Speaker: Abbott Laboratories, Allergan/Tobira, BMS, Falk, Fishawack, Genfit SA, Gilead, Kenes; Royalties: Elsevier Ltd (Davidson’s Principles & Practice of Medicine textbook)

    Elisabetta Bugianesi MD, PhD
    Disclosures:
    Consulting Fee: Bristol-Myers Squibb, Gilead Sciences, Inc., Intercept, Inventiva, Novo Nordisk

    Laurent Castera, MD, PhD
    Disclosures: Honorarium: Alexion, Echosens, MSD, Novo Nordisk, Pfizer, Inc.

    Kenneth Cusi, MD, FACP, FACE
    Disclosures: Research Support: Cirius, Echosens, Inventiva, Janssen, Nordic, Novartis, Novo Nordisk, Poxel, Zydus; Honorarium: Allergan, Amgen, AstraZeneca, BMS, Boehringer-Ingelheim, Cirius, Coherus, Esperion, Ionis, Janssen, Genentech

    Stephen Harrison, MD
    Disclosures: Advisory Board/Panel: 89 Bio Ltd, Akero Therapeutics, Inc., Altimmune, Inc., Arrowhead Pharmaceuticals, Inc., Axcella Health, Inc., CIVI Biopharma, Inc., Cymabay Therapeutics, Inc., Echosens North America, Inc., Foresite Labs, LLC, Galectin Therapeutics, Inc., Galmed Research & Dev, LTD, Genfit Corp, Gilead Science, Inc., Hepion Pharmaceuticals, Inc., Hightide Therapeutics, Inc., Histoindex PTE, LTD, Indalo Therapeutics, Inc., Intercept Pharmaceuticals, Inc., Madrigal Pharmaceuticals, Inc., Medpace, Inc., Metacrine, Inc., NGM Biopharmaceuticals, Inc., Northsea Therapeutics B.V., Novartis Pharmaceuticals Corp., Novo Nordisk, Pathai, Inc., Poxel, Prometic Pharma SMT LTD, Ridgeline Therapeutics, Sagimet Biosciences, Terns, Inc., Theratechologies; Consultant: AgomAB, Akero Therapeutics, Inc., Altimmune, Inc.

    Mazen Noureddin, MD, MHSc
    Disclosures: Advisory Board: 89BIO, Gilead, Intercept, Pfizer, Novartis, Novo Nordisk, Allergan, Blade, EchoSens, Fractyl, Terns, OWL, Siemens, Roche diagnostic and Abbott; Research Support: Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis, Shire, Viking and Zydus; Minor Stock Shareholder: Anaetos, Viking

    Vincent Wong, MD
    Disclosures:
    Consultant: 3V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Center for Outcomes Research in Liver Diseases, Echosens, Gilead Sciences, Hanmi Pharmaceutical, Intercept, Inventiva, Merck, Novartis, Novo Nordisk, Perspectum Diagnostics, Pfizer, ProSciento, Sagimet Biosciences, TARGET PharmaSolutions, Terns; Speaker Fee: AbbVie, Bristol-Myers Squibb, Echosens, Gilead Sciences

    Gena Dolson, MS
    No financial relationships with an ACCME-defined ineligible company in the last 24 months

    Victor B. Hatcher, PhD
    No financial relationships with an ACCME-defined ineligible company in the last 24 months

    Jim Kappler, PhD
    No financial relationships with an ACCME-defined ineligible company in the last 24 months

    Stacey JP Ullman, MHS
    No financial relationships with an ACCME-defined ineligible company in the last 24 months

  • Target Audience

    The educational design of this activity addresses the needs of hepatology/gastroenterology and endocrinology specialist physicians, nurse practitioners (NPs) and physician assistants (PAs), as well as other clinicians who treat patients with or at risk for nonalcoholic steatohepatitis (NASH).

  • Learning Objectives

    Upon completion of this activity, participants will be better able to:

    • Describe current epidemiologic and demographic data that can be used to help identify patients at a high risk for NASH
    • Determine which patients are at highest risk for advanced fibrosis and adverse clinical outcomes for whom pharmacologic therapy should be considered
    • Incorporate noninvasive tools into practice to support NASH staging, ongoing patient monitoring, and the appropriate use of biopsy
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and Integritas Communications. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Credit Designation Statement
    Albert Einstein College of Medicine-Montefiore Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Instructions to Receive Credit

    In order to receive credit, you must complete the following:

    1. Read the learning objectives, faculty disclosures, and accreditation information at the beginning of the activity
    2. Complete the activity pretest questions
    3. Review the activity content
    4. Complete the activity posttest questions with a score of 70% or better
    5. Complete the activity evaluation
  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Albert-Einstein College of Medicine-Montefiore Medical Center and Integritas Communications. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

  • Privacy Policy

    Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein) protects the privacy of personal and other information regarding participants and educational collaborators. Einstein will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting to the ACCME.

    Einstein maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you.

    Additional information regarding Albert Einstein College of Medicine-Montefiore Medical Center's Privacy Policy can be viewed at https://www.mecme.org/PrivacyStatement.aspx

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Albert Einstein College of Medicine-Montefiore Medical Center and Integritas Communications.

  • Commercial Support

    This activity is supported by an independent educational grant from Pfizer, Inc.

  • Acknowledgments

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • In Collaboration with

  • Overview

    The use of noninvasive tools in NAFLD/NASH has become more prevalent over the last several years, with increased availability of imaging and serum-based tools. A forum of experts convened to discuss optimal use of these tools in NAFLD/NASH using a series of clinical assertion statements. These statements covered screening patients with diabetes, applicability of liver enzymes in determining fibrosis stage, use of transient elastography and blood-based tools, such as the Enhanced Liver Fibrosis test, and potential genetic testing. Here, Drs Jacobson and Younossi summarize the research and discussion points from the forum.

  • Disclosure of Conflicts of Interest

    The “Policy on Identification, Mitigation and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that all individuals in control of educational content of a CME/CE activity disclose all financial relationships with ineligible companies* within the previous 24-month period. Any individual whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present. All relevant financial relationships and potential conflicts of interest are mitigated prior to the activity.

    *The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

    Ira M. Jacobson, MD
    Disclosures: Grant/Research Support: Assembly Biosciences, Bristol Myers Squibb, Durect, Eli Lilly, Enanta, Genfit, Gilead, Janssen and Myr; Honorarium: AbbVie, Aligos, Arbutus, Arrowhead, Assembly Biosciences, Bristol Myers Squibb, Galmed, Gilead, Glaxo, Intercept, Janssen, Poptest and Redhill

    Zobair M. Younossi MD, MPH, FACP, FACG, AGAF, FAASLD
    Disclosures: Consultant: Abbvie, Bristol-Myers Squibb, Genfit, Gilead Sciences, Intercept, Madrigal, Merck, NovoNordisk, Siemens, Terns Pharmaceuticals, Inc., Viking Therapeutics

    Aaron Z. Tokayer, MD
    No financial relationships with an ACCME-defined ineligible company in the last 24 months

    Planning Committee Members
    Quentin M. Anstee, PhD, FRCP
    Disclosures:
    Research Grant Funding: Abbvie, Allergan/Tobira, AstraZeneca, GlaxoSmithKline, Glympse Bio, Novartis Pharma AG, Pfizer Ltd., Vertex. Active Research Collaborations (including research collaborations supported through the EU IMI2 LITMUS Consortium*): Abbvie, Antaros Medical*, Allergan/Tobira*, AstraZeneca*, BMS*, Boehringer Ingelheim International GMBH*, Echosens*, Ellegaard Gottingen Minipigs AS*, Eli Lilly & Company Ltd.*, Exalenz Bioscience Ltd.*, Genfit SA*, Glympse Bio, GlaxoSmithKline, HistoIndex*, Intercept Pharma Europe Ltd.*, iXscient Ltd.*, Nordic Bioscience*, Novartis Pharma AG*, Novo Nordisk A/S*, One Way Liver Genomics SL*, Perspectum Diagnostics*, Pfizer Ltd.*, Resoundant*, Sanofi-Aventis Deutschland GMBH*, SomaLogic Inc.*, Takeda Pharmaceuticals International SA*; Consultancy: 89Bio, Abbott Laboratories, Acuitas Medical, Allergan/Tobira, Altimmune, AstraZeneca, Axcella, Blade, BMS, BNN Cardio, Celgene, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company Ltd., Galmed, Genentech, Genfit SA, Gilead, Grunthal, HistoIndex, Indalo, Imperial Innovations, Intercept Pharma Europe Ltd., Inventiva, IQVIA, Janssen, Madrigal, MedImmune, Metacrine, NewGene, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S, PathAI, Pfizer Ltd., Poxel, ProSciento, Raptor Pharma, Servier, Terns, Viking Therapeutics; Speaker: Abbott Laboratories, Allergan/Tobira, BMS, Falk, Fishawack, Genfit SA, Gilead, Kenes; Royalties: Elsevier Ltd (Davidson’s Principles & Practice of Medicine textbook)

    Elisabetta Bugianesi MD, PhD
    Disclosures:
    Consulting Fee: Bristol-Myers Squibb, Gilead Sciences, Inc., Intercept, Inventiva, Novo Nordisk

    Laurent Castera, MD, PhD
    Disclosures: Honorarium: Alexion, Echosens, MSD, Novo Nordisk, Pfizer, Inc.

    Kenneth Cusi, MD, FACP, FACE
    Disclosures: Research Support: Cirius, Echosens, Inventiva, Janssen, Nordic, Novartis, Novo Nordisk, Poxel, Zydus; Honorarium: Allergan, Amgen, AstraZeneca, BMS, Boehringer-Ingelheim, Cirius, Coherus, Esperion, Ionis, Janssen, Genentech

    Stephen Harrison, MD
    Disclosures: Advisory Board/Panel: 89 Bio Ltd, Akero Therapeutics, Inc., Altimmune, Inc., Arrowhead Pharmaceuticals, Inc., Axcella Health, Inc., CIVI Biopharma, Inc., Cymabay Therapeutics, Inc., Echosens North America, Inc., Foresite Labs, LLC, Galectin Therapeutics, Inc., Galmed Research & Dev, LTD, Genfit Corp, Gilead Science, Inc., Hepion Pharmaceuticals, Inc., Hightide Therapeutics, Inc., Histoindex PTE, LTD, Indalo Therapeutics, Inc., Intercept Pharmaceuticals, Inc., Madrigal Pharmaceuticals, Inc., Medpace, Inc., Metacrine, Inc., NGM Biopharmaceuticals, Inc., Northsea Therapeutics B.V., Novartis Pharmaceuticals Corp., Novo Nordisk, Pathai, Inc., Poxel, Prometic Pharma SMT LTD, Ridgeline Therapeutics, Sagimet Biosciences, Terns, Inc., Theratechologies; Consultant: AgomAB, Akero Therapeutics, Inc., Altimmune, Inc.

    Mazen Noureddin, MD, MHSc
    Disclosures: Advisory Board: 89BIO, Gilead, Intercept, Pfizer, Novartis, Novo Nordisk, Allergan, Blade, EchoSens, Fractyl, Terns, OWL, Siemens, Roche diagnostic and Abbott; Research Support: Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis, Shire, Viking and Zydus; Minor Stock Shareholder: Anaetos, Viking

    Vincent Wong, MD
    Disclosures:
    Consultant: 3V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Center for Outcomes Research in Liver Diseases, Echosens, Gilead Sciences, Hanmi Pharmaceutical, Intercept, Inventiva, Merck, Novartis, Novo Nordisk, Perspectum Diagnostics, Pfizer, ProSciento, Sagimet Biosciences, TARGET PharmaSolutions, Terns; Speaker Fee: AbbVie, Bristol-Myers Squibb, Echosens, Gilead Sciences

    Gena Dolson, MS
    No financial relationships with an ACCME-defined ineligible company in the last 24 months

    Victor B. Hatcher, PhD
    No financial relationships with an ACCME-defined ineligible company in the last 24 months

    Jim Kappler, PhD
    No financial relationships with an ACCME-defined ineligible company in the last 24 months

    Stacey JP Ullman, MHS
    No financial relationships with an ACCME-defined ineligible company in the last 24 months

  • Target Audience

    The educational design of this activity addresses the needs of hepatology/gastroenterology and endocrinology specialist physicians, nurse practitioners (NPs) and physician assistants (PAs), as well as other clinicians who treat patients with or at risk for nonalcoholic steatohepatitis (NASH).

  • Learning Objectives

    Upon completion of this activity, participants will be better able to:

    • Describe current epidemiologic and demographic data that can be used to help identify patients at a high risk for NASH
    • Determine which patients are at highest risk for advanced fibrosis and adverse clinical outcomes for whom pharmacologic therapy should be considered
    • Incorporate noninvasive tools into practice to support NASH staging, ongoing patient monitoring, and the appropriate use of biopsy
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and Integritas Communications. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Credit Designation Statement
    Albert Einstein College of Medicine-Montefiore Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Instructions to Receive Credit

    In order to receive credit, you must complete the following:

    1. Read the learning objectives, faculty disclosures, and accreditation information at the beginning of the activity
    2. Complete the activity pretest questions
    3. Review the activity content
    4. Complete the activity posttest questions with a score of 70% or better
    5. Complete the activity evaluation
  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Albert-Einstein College of Medicine-Montefiore Medical Center and Integritas Communications. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

  • Privacy Policy

    Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein) protects the privacy of personal and other information regarding participants and educational collaborators. Einstein will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting to the ACCME.

    Einstein maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you.

    Additional information regarding Albert Einstein College of Medicine-Montefiore Medical Center's Privacy Policy can be viewed at https://www.mecme.org/PrivacyStatement.aspx

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Albert Einstein College of Medicine-Montefiore Medical Center and Integritas Communications.

  • Commercial Support

    This activity is supported by an independent educational grant from Pfizer, Inc.

  • Acknowledgments

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule3 Oct 2023